Skip to main content
OpenTrials

Clinical trial condition

Diffuse Large B-cell Lymphoma

Explore clinical trials studying Diffuse Large B-cell Lymphoma. Study availability and eligibility vary by location and protocol.

213 public trials 54 recruiting studies
Refine in advanced search Browse all conditions

Diffuse Large B-cell Lymphoma trial results

Completed

New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

NCT02329080

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Facultni nemocnice Brno, Czechia
  • FNKV (Facultni Nemocnice Kralovske Vinohrady) Prague, Czechia
  • Vseobecna facultni nemocnice v Praze Prague, Czechia
  • Spedali Civili Brescia, Italy
View all 36 locations
View Trial Details
Completed

Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

NCT03742258

Conditions
Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, +15 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Northwestern Lake Forest Hospital Lake Forest, Illinois, United States
View Trial Details
Completed

Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

NCT03939182

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Commack Commack, New York, United States
  • Memorial Sloan Kettering Westchester Harrison, New York, United States
View Trial Details
Completed

Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

NCT03263026

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Oncology Specialties: Clearview Cancer Institute Huntsville, Alabama, United States
  • University of Arizona Tucson, Arizona, United States
  • Central Arkansas Radiation Therapy Institute Little Rock, Arkansas, United States
  • Desert Hematology Rancho Mirage, California, United States
View all 39 locations
View Trial Details
Completed

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

NCT03955783

Conditions
Acute Myeloid Leukemia, Diffuse Large B-cell Lymphoma, Hematologic Diseases, +15 more
Locations
  • Roswell Park Cancer Center Buffalo, New York, United States
  • University Hospitals of Cleveland Cleveland, Ohio, United States
  • Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States
  • University of Texas Southwestern Medical Center Dallas, Texas, United States
View Trial Details
Completed

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

NCT03520920

Conditions
Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Hemic and Lymphatic Diseases, +13 more
Locations
  • Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology Wuhan, Hubei, China
  • The Affiliated Hospital of Xuzhou Medical University Xuzhou, Jiangsu, China
  • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai Municipality, China
View Trial Details
Completed

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

NCT03145064

Conditions
Diffuse Large B-cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +13 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • The First Affiliated Hospital of Soochow University Branch Shizi Suzhou, Jiangsu, China
View Trial Details
Completed

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

NCT04134936

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • MorphoSys Research Site Tucson, Arizona, United States
  • MorphoSys Research Site Anaheim, California, United States
  • MorphoSys Research Site Duarte, California, United States
  • MorphoSys Research Site Encinitas, California, United States
View all 70 locations
View Trial Details

Related conditions